Hope Tribune

Glaucoma Pipeline | Clinical Trials, Key Companies – Nicox Ophthalmics, pH Pharma, Santen Pharmaceuticals

 Breaking News
  • No posts were found

Glaucoma Pipeline | Clinical Trials, Key Companies – Nicox Ophthalmics, pH Pharma, Santen Pharmaceuticals

November 08
17:38 2023
Glaucoma Pipeline | Clinical Trials, Key Companies - Nicox Ophthalmics, pH Pharma, Santen Pharmaceuticals
DelveInsight Business Research LLP
DelveInsight’s, “Glaucoma – Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s, “Glaucoma – Pipeline Insight, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Highlights for Glaucoma Pipeline 

  • The Key Companies working for Glaucoma include Santen Pharmaceuticals, Visiox Pharma, Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, and many others 
  • The Key Therapies for Glaucoma include GmbH NCX 470, DE-126, POLAT 001, BTQ-1902, ST266 and many others 

 

Got queries? Click here to know more about the Glaucoma Pipeline 

Glaucoma Overview

Glaucoma is a group of eye conditions that damage the optic nerve. The optic nerve sends visual information from eye to the brain and is vital for good vision. Damage to the optic nerve is often related to high pressure in your eye. But glaucoma can happen even with normal eye pressure. Many forms of glaucoma have no warning signs. The effect is so gradual that you may not notice a change in vision until the condition is in its later stages. It’s important to have regular eye exams that include measurements of your eye pressure. If glaucoma is recognized early, vision loss can be slowed or prevented. If you have glaucoma, you’ll need treatment or monitoring for the rest of your life. Based on the type of Glaucoma, the symptoms are different. For open-angle glaucoma there are no symptoms in the early stages, gradually, patchy blind spots appear on side/ Peripheral vision and in later stages, there is difficulty seeing things in central vision.

Learn more by requesting for sample @ Glaucoma Pipeline 

Glaucoma Key Companies  

  • Santen Pharmaceuticals
  • Visiox Pharma
  • Nicox Ophthalmics
  •  pH Pharma
  • Omikron Italia
  • Tarsier Pharma                                                                                    And many others 

Glaucoma Therapies 

  • GmbH NCX 470
  • DE-126
  • POLAT 001
  • BTQ-1902:
  • ST266

And many others 

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Glaucoma
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  • Glaucoma  Emerging Therapies
  • Glaucoma  Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Glaucoma  Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer
  •  About DelveInsight

Click here to read more about Glaucoma Pipeline 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories